Phenominer Database Results (30 results)

 

How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 18 641.0 cells/ul 161.46 685.0 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU 111091 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 18 987.0 cells/ul 23.81 101.0 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 111092 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 21 2.1 x 10E6 cells/ml 0.08 0.36 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2+ Ta1 111105 3196
BDIX/OrlCrl blood CD25 cell count sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 63 days-77 days 16 661.0 cells/ul 56.75 227.0 fluorescence-activated cell sorting method 0.0 0 days baseline baseline saline control group 111086 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 16 1631.0 cells/ul 149.75 599.0 fluorescence-activated cell sorting method 0.0 28 days saline control saline control group 111088 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) then sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 16 1.57 x 1000 cells/ul 0.06 0.24 fluorescence-activated cell sorting method 0.0 48 days saline control saline control group 111109 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 18 1.88 x 1000 cells/ul 0.07 0.29 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 111112 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 18 588.0 cells/ul 49.73 211.0 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU 111090 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 18 2267.0 cells/ul 74.25 315.0 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2 111093 3196
BDIX/OrlCrl blood CD8 cell count sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 63 days-77 days 16 1.83 x 10E6 cells/ml 0.23 0.93 fluorescence-activated cell sorting method 0.0 0 days baseline baseline saline control group 111096 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 16 1.17 x 10E6 cells/ml 0.07 0.3 fluorescence-activated cell sorting method 0.0 28 days saline control saline control group 111098 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 18 0.43 x 10E6 cells/ml 0.02 0.11 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU 111100 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 77 days-91 days 16 2294.0 cells/ul 205.0 820.0 fluorescence-activated cell sorting method 0.0 14 days sham saline control group 111087 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 77 days-91 days 16 2.76 x 1000 cells/ul 0.24 0.96 fluorescence-activated cell sorting method 0.0 14 days sham saline control group 111107 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 16 1.81 x 1000 cells/ul 0.08 0.32 fluorescence-activated cell sorting method 0.0 28 days saline control saline control group 111108 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 18 0.96 x 1000 cells/ul 0.06 0.25 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU 111110 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 18 0.3 x 1000 cells/ul 0.08 0.36 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU 111111 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 21 1215.0 cells/ul 87.07 399.0 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 +Ta1 111094 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 77 days-91 days 16 2.25 x 10E6 cells/ml 0.18 0.72 fluorescence-activated cell sorting method 0.0 14 days sham saline control group 111097 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) then sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 16 0.92 x 10E6 cells/ml 0.03 0.1 fluorescence-activated cell sorting method 0.0 48 days saline control saline control group 111099 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 18 0.69 x 10E6 cells/ml 0.05 0.23 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU 111101 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 18 1.23 x 10E6 cells/ml 0.05 0.23 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2 111103 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 21 2.0 x 10E6 cells/ml 0.11 0.51 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 +Ta1 111104 3196
BDIX/OrlCrl blood CD4 cell count sodium chloride solution (2 ml) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 63 days-77 days 16 2.06 x 1000 cells/ul 0.17 0.67 fluorescence-activated cell sorting method 0.0 0 days baseline baseline saline control group 111106 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 21 3.39 x 1000 cells/ul 0.16 0.72 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 +Ta1 111114 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 21 3664.0 cells/ul 56.74 260.0 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2+ Ta1 111095 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 18 1.1 x 10E6 cells/ml 0.02 0.09 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 111102 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) then sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 16 1917.0 cells/ul 105.25 421.0 fluorescence-activated cell sorting method 0.0 48 days saline control saline control group 111089 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 21 4.5 x 1000 cells/ul 0.23 1.05 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2+ Ta1 111115 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 18 2.22 x 1000 cells/ul 0.06 0.26 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2 111113 3196